 |
|
|
|
 |
|
|
|
| Article 1 to 10 out of 83
|
|
-
NicOx announces initiation of first phase 1 study of investigational nitric oxide-donating agent in hypertensive patients
(14 May 2008)
NicOx S.A. announced that Merck & Co., Inc. has initiated the first in a series of planned clinical studies, in mild to moderate hypertensive patients, under the companies' collaborative agreement to develop new nitric oxide-donating ......
-
NicOx announces U.S. phase 2a results for PF-03187207 and gives an update on continuing NO-prostaglandin program
(07 May 2008)
NicOx S.A. announced the results of a U.S. phase 2 study, conducted by its partner Pfizer Inc, which compared the safety and efficacy of various doses of PF-03187207 to Xalatan® (latanoprost) 0.005% in patients with primary open-angle glaucoma ......
-
A new iconic drug information system inspired by road signs
(30 Apr 2008)
Although drug prescriptions are notoriously difficult to read, prescribing errors due to a lack of knowledge of drug properties are a worse problem. Now, a new information icon system has been developed by researchers in France. The researchers ......
-
Servier Integrates Definiens Technology in Translational Research
(17 Apr 2008)
Servier decided to install Definiens technology in its two core Discovery Research facilities located in Suresnes and Croissy-sur-Seine. Preceded by several successful test projects, this strategic decision was made internally in fall 2007. ......
-
Scientists develop strategy to rapidly describe outbreak strains with next-generation DNA sequencing
(11 Apr 2008)
In the event of an outbreak or a bioterrorist attack, rapid identification of the genetic changes responsible for virulence or drug resistance is essential to mounting an effective response. Standard DNA sequencing and analysis of a pathogen ......
-
NicOx signs agreement for the commercial manufacture of naproxcinod drug substance
(20 Mar 2008)
NicOx S.A. announced it has signed an agreement with the fine chemical company Archimica, for the commercial manufacturing and supply of naproxcinod drug substance (or active pharmaceutical ingredient, API). Naproxcinod is NicOx' lead ......
-
NicOx initiates two large ABPM studies for naproxcinod in hypertensive patients with osteoarthritis
(05 Mar 2008)
NicOx S.A. announced the initiation of two large clinical pharmacology studies in the United States, which will assess the blood pressure profile of naproxcinod in comparison to ibuprofen and naproxen, using the Ambulatory Blood Pressure ......
-
METabolic EXplorer achieves a performance milestone in its methionine project
(29 Feb 2008)
L-methionine ready to enter industrial pilot phase
METabolic EXplorer announced the achievement of technical and economic performance levels which will trigger the industrial pilot phase of its L-methionine project. METabolic EXplorer has developed and optimized a proprietary fermentation ......
-
Dyax Enters Into Antibody Agreements with Sanofi-aventis for the Fully Human Monoclonal Antibody and Phage Display Technology
(13 Feb 2008)
Dyax Retains Co-development Rights and Profit Sharing for Certain Partner Programs
Dyax Corp. and sanofi-aventis announced that they have entered into agreements in which sanofi-aventis has been granted an exclusive worldwide license for the development and commercialization of the fully human monoclonal antibody DX-2240, as ......
-
Researchers identify a worldwide-distributed clone of bacteria responsible for Legionnaire's disease
(06 Feb 2008)
A study published online in Genome Research describes new insights into Legionella pneumophila, the bacteria responsible for most cases of Legionnaires' disease. This report investigates the genetic background of L. pneumophila, provides clues ......
|
|
|
Top